Reporting on the third quarter ended Dec. 31, Prestige Brands' CEO Matthew Mannelly told analysts he is "cautiously optimistic" regarding cough-cold reorders given the high consumption levels at retail in late December through January.

Prestige Brands closed out its fiscal 2012 ended March 31 on a high note with $441.1 million in revenues for the year, up 31.1%. And fiscal 2013 is looking promising as the company will have full-year contributions from its 17 acquired over-the-counter brands from GlaxoSmithKline.

You can expect to see quite a bit of co-promotional activity between PediaCare and Little Remedies in the 2011-2012 cough-cold season, Prestige Brands president and CEO Matthew Mannelly told investors Wednesday morning at the Bank of America Merrill Lynch 2011 Consumer Conference held here.

Prestige Brands posted gains of 22.7% in revenue, reaching $90.6 million for its third quarter ended Dec. 31.